NSG 552 PSYCHOPHARMACOLOGY FINAL
EXAM MASTER TEST BANK (2026 – 2027)
300 Board-Style Multiple-Choice Questions
with Detailed Rationales | Wilkes
University PMHNP Program | FNP &
PMHNP Board Prep Aligned | 2026 Edition.
DESCRIPTION
NSG 552 Psychopharmacology Final Exam Master Test Bank is
a comprehensive 300-question practice resource designed for
graduate nursing students enrolled in NSG 552:
Psychopharmacology at Wilkes University. This course assists
the Psychiatric-Mental Health Nurse Practitioner to develop
competence in prescribing and monitoring
psychopharmacological agents used in the treatment of
common psychiatric-mental health disorders across the lifespan
.
,This test bank mirrors the ANCC PMHNP board certification
blueprint and AANPCB FNP blueprint, covering the five content
domains tested: Scientific Foundation (22%), Advanced
Practice Skills (27%), Diagnosis and Treatment (22%),
Psychotherapy and Related Theories (11%), and Ethics, Legal
Principles, and Cultural Care (17%) . Each question includes a
verified correct answer and an evidence-based rationale
grounded in current clinical guidelines and neurobiological
principles.
Key Sections Covered:
Section I: Principles of Psychopharmacology (Q1–40) –
Pharmacokinetics, pharmacodynamics, CYP450
interactions, blood-brain barrier, pharmacogenomics, DEA
regulations
Section II: Antidepressants (Q41–90) – SSRIs, SNRIs, TCAs,
MAOIs, atypical agents, serotonin syndrome,
discontinuation syndrome
Section III: Antipsychotics (Q91–140) – FGAs, SGAs, EPS
spectrum, NMS, metabolic syndrome, clozapine REMS
Section IV: Mood Stabilizers (Q141–180) – Lithium,
valproate, carbamazepine, lamotrigine, toxicity monitoring
Section V: Anxiolytics & Sedative-Hypnotics (Q181–220) –
Benzodiazepines, buspirone, Z-drugs, dependence,
tapering
, Section VI: ADHD Medications (Q221–255) –
Methylphenidate, amphetamines, atomoxetine, alpha-2
agonists, Schedule II regulations
Section VII: Substance Use Disorder Pharmacotherapy
(Q256–285) – Alcohol, opioid, and nicotine use disorder
treatments, MAT
Section VIII: Special Populations & Integrated Scenarios
(Q286–300) – Pediatric, geriatric, pregnancy
considerations, clinical judgment
How to Use: Work through each section systematically, review
rationales for missed questions, and use the section-specific
breakdowns to identify areas requiring additional study.
SECTION I: PRINCIPLES OF PSYCHOPHARMACOLOGY
(Questions 1–40)
1. A 9-year-old male is diagnosed with ADHD, predominantly
inattentive type. Which of the following best describes the
mechanism of action of Methylphenidate in treating this
condition?
A. It stimulates the direct release of serotonin from the
presynaptic vesicles.
B. It acts primarily by blocking the reuptake of norepinephrine
and dopamine via transporter inhibition.
, C. It acts as a potent agonist at the post-synaptic alpha-2
adrenergic receptors.
D. It inhibits the monoamine oxidase enzyme system to
increase synaptic concentrations of GABA.
Answer: B
Rationale: Methylphenidate functions by inhibiting the
reuptake of dopamine and norepinephrine, thereby increasing
their availability in the synaptic cleft. This mechanism helps to
enhance focus and reduce impulsivity in patients with ADHD.
Unlike amphetamines, it does not primarily promote the efflux
or release of these neurotransmitters from storage vesicles .
2. Which cytochrome P450 enzyme is primarily responsible for
the metabolism of fluoxetine, paroxetine, and many tricyclic
antidepressants?
A. CYP3A4
B. CYP2D6
C. CYP1A2
D. CYP2C19
Answer: B
Rationale: CYP2D6 is a major enzyme involved in the
metabolism of many antidepressants, including fluoxetine,
paroxetine, and tricyclic antidepressants. Genetic
EXAM MASTER TEST BANK (2026 – 2027)
300 Board-Style Multiple-Choice Questions
with Detailed Rationales | Wilkes
University PMHNP Program | FNP &
PMHNP Board Prep Aligned | 2026 Edition.
DESCRIPTION
NSG 552 Psychopharmacology Final Exam Master Test Bank is
a comprehensive 300-question practice resource designed for
graduate nursing students enrolled in NSG 552:
Psychopharmacology at Wilkes University. This course assists
the Psychiatric-Mental Health Nurse Practitioner to develop
competence in prescribing and monitoring
psychopharmacological agents used in the treatment of
common psychiatric-mental health disorders across the lifespan
.
,This test bank mirrors the ANCC PMHNP board certification
blueprint and AANPCB FNP blueprint, covering the five content
domains tested: Scientific Foundation (22%), Advanced
Practice Skills (27%), Diagnosis and Treatment (22%),
Psychotherapy and Related Theories (11%), and Ethics, Legal
Principles, and Cultural Care (17%) . Each question includes a
verified correct answer and an evidence-based rationale
grounded in current clinical guidelines and neurobiological
principles.
Key Sections Covered:
Section I: Principles of Psychopharmacology (Q1–40) –
Pharmacokinetics, pharmacodynamics, CYP450
interactions, blood-brain barrier, pharmacogenomics, DEA
regulations
Section II: Antidepressants (Q41–90) – SSRIs, SNRIs, TCAs,
MAOIs, atypical agents, serotonin syndrome,
discontinuation syndrome
Section III: Antipsychotics (Q91–140) – FGAs, SGAs, EPS
spectrum, NMS, metabolic syndrome, clozapine REMS
Section IV: Mood Stabilizers (Q141–180) – Lithium,
valproate, carbamazepine, lamotrigine, toxicity monitoring
Section V: Anxiolytics & Sedative-Hypnotics (Q181–220) –
Benzodiazepines, buspirone, Z-drugs, dependence,
tapering
, Section VI: ADHD Medications (Q221–255) –
Methylphenidate, amphetamines, atomoxetine, alpha-2
agonists, Schedule II regulations
Section VII: Substance Use Disorder Pharmacotherapy
(Q256–285) – Alcohol, opioid, and nicotine use disorder
treatments, MAT
Section VIII: Special Populations & Integrated Scenarios
(Q286–300) – Pediatric, geriatric, pregnancy
considerations, clinical judgment
How to Use: Work through each section systematically, review
rationales for missed questions, and use the section-specific
breakdowns to identify areas requiring additional study.
SECTION I: PRINCIPLES OF PSYCHOPHARMACOLOGY
(Questions 1–40)
1. A 9-year-old male is diagnosed with ADHD, predominantly
inattentive type. Which of the following best describes the
mechanism of action of Methylphenidate in treating this
condition?
A. It stimulates the direct release of serotonin from the
presynaptic vesicles.
B. It acts primarily by blocking the reuptake of norepinephrine
and dopamine via transporter inhibition.
, C. It acts as a potent agonist at the post-synaptic alpha-2
adrenergic receptors.
D. It inhibits the monoamine oxidase enzyme system to
increase synaptic concentrations of GABA.
Answer: B
Rationale: Methylphenidate functions by inhibiting the
reuptake of dopamine and norepinephrine, thereby increasing
their availability in the synaptic cleft. This mechanism helps to
enhance focus and reduce impulsivity in patients with ADHD.
Unlike amphetamines, it does not primarily promote the efflux
or release of these neurotransmitters from storage vesicles .
2. Which cytochrome P450 enzyme is primarily responsible for
the metabolism of fluoxetine, paroxetine, and many tricyclic
antidepressants?
A. CYP3A4
B. CYP2D6
C. CYP1A2
D. CYP2C19
Answer: B
Rationale: CYP2D6 is a major enzyme involved in the
metabolism of many antidepressants, including fluoxetine,
paroxetine, and tricyclic antidepressants. Genetic
